Piñeiro PD, Domínguez CJ, Hernández PJC

Language: Spanish
References: 7
Page: 1-5
PDF size: 297.41 Kb.

ABSTRACT

The contemporary rise of new paradigms within medical sciences, such as personalized medicine, a more effective oncological resection is pursued, with new surgical margins based on tumor stage. To achieve these outcomes, some techniques, such as radioimmunoguided surgery, are expanding. In Cuba, biotechnological advances have allowed the development of world-leading drugs, such as nimotuzumab, a monoclonal antibody directed against the epidermal growth factor receptor, overexpressed in multiple malignant tumors of epithelial origin. Marking it with a radioisotope can help the surgeon in the precise determination of tumor extent (radioguided) of these malignancies during the surgical act.

REFERENCES

1. Mortalidad. En: Zaca Peña E, editor. Anuario estadístico de salud 2010. La Habana: Dirección nacional de registros médicos y estadísticas de salud del Ministerio de Salud Pública; 2017.

2. Van de Velde CJH, Boelens PG, Borras JM, Coebergh JW, Cervantes A, Blomqvist L, et al. EURECCA colorectal: Multidisciplinary management: European consensus conference colon & rectum. Eur J Cancer. 2014;50:1–34.

3. Kaur S, Venktaraman G, Jain M, Senapati S, Garg PK, Batra SK, et al. Recent trends in antibody-based oncologic imaging. Cancer Let. 2012;315:97–111.

4. Tsuchimochi M, Hayama K. Intraoperative gamma cameras for radioguided surgery: Technical characteristics, performance parameters, and clinical applications. Phys Med. 2013;29:126e-38.

5. Aitken DR, Hinkle GH, Thurston MO. A gammadetecting probe for radioimmune detection of CEA producing tumors. Successful experimental use and clinical case report. Dis Colon Rectum. 1984;27:279–82.

6. Tiernan JP, Ansari I, Hirst NA, Millner PA, Hughes TA, Jayne DG, et al. Intra-operative tumour detection and staging in colorectal cancer surgery. Colorectal Dis. 2012;14:e510-20.

7. Torres LA, Perera A, Batista JF, Hernandez A, Crombet T, Ramos M, et al. Phase I/II clinical trial of the humanized anti-EGF-r monoclonal antibody h-R3 labelled with 99mTc in patients with tumour of epithelial origin. Nucl Med Commun. 2005;26:1049–57.